Alflutinib methanesulfonate( AST2818 | AST-2818 | ASK120067 )

Catalog No. M13393 CAS No. 2130958-55-1

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Group Booking Get Quotation Bulk Inquiry Add to Cart

Product Name

Alflutinib methanesulfonate
Note

Research use only, not for human use.
Brief Description

Alflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.
Description

Alflutinib methanesulfonate (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.Lung Cancer Phase 1 Clinical(In Vitro):Alflutinib (Furmonertinib) mesylate is designed to inhibit EGFR active mutations as well as the T790M acquired resistant mutation.
In Vitro

Firmonertinib mesylate can inhibit EGFR active mutations as well as the T790M acquired resistant mutation.
In Vivo

——
Synonyms

AST2818 | AST-2818 | ASK120067
Pathway

Angiogenesis
Target

EGFR
Recptor

EGFR
Research Area

Cancer
Indication

Lung Cancer

CAS Number

2130958-55-1
Formula Weight

664.705
Molecular Formula

C29H35F3N8O5S
Purity

>98% (HPLC)
Solubility

DMSO : 5 mg/mL 7.52 mM
SMILES

CN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)c3cn(C)c4ccccc34)cc1NC(=O)C=C.CS(=O)(=O)O
Chemical Name

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide methanesulfonate

1. PCT Int. Appl. (2017), WO 2017152707 A1 20170914. 2. PCT Int. Appl. (2017), WO 2017152706 A1 20170914.

Calculator

molnova catalog